期刊文献+

Metformin induces apoptosis of pancreatic cancer cells 被引量:13

Metformin induces apoptosis of pancreatic cancer cells
下载PDF
导出
摘要 AIM:To assess the role and mechanism of metformin in inducing apoptosis of pancreatic cancer cells.METHODS:The human pancreatic cancer cell lines ASPC-1,BxPc-3,PANC-1 and SW1990 were exposed to metformin.The inhibition of cell proliferation and colony formation via apoptosis induction and S phase arrest in pancreatic cancer cell lines of metformin was tested.RESULTS:In each pancreatic cancer cell line tested,metformin inhibited cell proliferation in a dose dependent manner in MTS(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assays).Flow cytometric analysis showed that metformin reduced the number of cells in G1 and increased the percentage of cells in S phase as well as the apoptotic fraction.Enzymelinked immunosorbent assay(ELISA) showed that metformin induced apoptosis in all pancreatic cancer cell lines.In Western blot studies,metformin induced poly-ADP-ribose polymerase(PARP) cleavage(an indicator of caspase activation) in all pancreatic cancer cell lines.The general caspase inhibitor(VAD-fmk) completely abolished metformin-induced PARP cleavage and apoptosis in ASPC-1 BxPc-3 and PANC-1,the caspase-8 specific inhibitor(IETD-fmk) and the caspase-9 specific inhibitor(LEHD-fmk) only partially abrogated metformin-induced apoptosis and PARP cleavage in BxPc-3 and PANC-1 cells.We also observed that metformin treatment dramatically reduced epidermal growth factor receptor(EGFR) and phosphorylated mitogen activated protein kinase(P-MAPK) in both a time-and dose-dependent manner in all cell lines tested.CONCLUSION:Metformin significantly inhibits cell proliferation and apoptosis in all pancreatic cell lines.And the metformin-induced apoptosis is associated with PARP cleavage,activation of caspase-3,-8,and-9 in a time-and dose-dependent manner.Hence,both caspase-8 and-9-initiated apoptotic signaling pathways contribute to metformin-induced apoptosis in pancreatic cell lines. AIM:To assess the role and mechanism of metformin in inducing apoptosis of pancreatic cancer cells.METHODS:The human pancreatic cancer cell lines ASPC-1,BxPc-3,PANC-1 and SW1990 were exposed to metformin.The inhibition of cell proliferation and colony formation via apoptosis induction and S phase arrest in pancreatic cancer cell lines of metformin was tested.RESULTS:In each pancreatic cancer cell line tested,metformin inhibited cell proliferation in a dose dependent manner in MTS(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assays).Flow cytometric analysis showed that metformin reduced the number of cells in G1 and increased the percentage of cells in S phase as well as the apoptotic fraction.Enzymelinked immunosorbent assay(ELISA) showed that metformin induced apoptosis in all pancreatic cancer cell lines.In Western blot studies,metformin induced poly-ADP-ribose polymerase(PARP) cleavage(an indicator of caspase activation) in all pancreatic cancer cell lines.The general caspase inhibitor(VAD-fmk) completely abolished metformin-induced PARP cleavage and apoptosis in ASPC-1 BxPc-3 and PANC-1,the caspase-8 specific inhibitor(IETD-fmk) and the caspase-9 specific inhibitor(LEHD-fmk) only partially abrogated metformin-induced apoptosis and PARP cleavage in BxPc-3 and PANC-1 cells.We also observed that metformin treatment dramatically reduced epidermal growth factor receptor(EGFR) and phosphorylated mitogen activated protein kinase(P-MAPK) in both a time-and dose-dependent manner in all cell lines tested.CONCLUSION:Metformin significantly inhibits cell proliferation and apoptosis in all pancreatic cell lines.And the metformin-induced apoptosis is associated with PARP cleavage,activation of caspase-3,-8,and-9 in a time-and dose-dependent manner.Hence,both caspase-8 and-9-initiated apoptotic signaling pathways contribute to metformin-induced apoptosis in pancreatic cell lines.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第47期7192-7198,共7页 世界胃肠病学杂志(英文版)
基金 Supported by The National Natural Science Foundation of China,No.30700360
关键词 甲福明二甲双胍 胰腺癌 分子分级 细胞凋亡 Metformin Pancreatic cancer Molecular classification Apoptosis
  • 相关文献

参考文献1

二级参考文献16

  • 1[1]Burris HA 3rd,Moore MJ,Andersen J,Green MR,Rothenberg ML,Modiano MR,Cripps MC,Portenoy RK,Storniolo AM,Tarassoff P,Nelson R,Dorr FA,Stephens CD,Von Hoff DD.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial.J Clin Oncol 1997; 15:2403-2413
  • 2[2]Heinemann V.Gemcitabine in the treatment of advanced pancreatic cancer:a comparative analysis of randomized trials.Semin Oncol 2002; 29:9-16
  • 3[3]Moore MJ,Goldstein D,Hamm J,Finger A,Hecht J,Gallinger S,Au H,Ding K,Christy-Bittel J,Parulekar W.Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer.A phase Ⅲ trial of the National Cancer Institute of Canada Clinicals trials group[NCIC-CTG].Proc Am Soc Clin Oncol 2005; 23:1
  • 4[4]Cunningham D,Chau I,Stocken D,Davies C,Dunn J,Valle J,Smith D,Steward W,Harper P,Neoptolemos J.Phase Ⅲ randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer.Eur J Cancer Suppl 2005; 3:11
  • 5[5]Saad ED,Machado MC,Wajsbrot D,Abramoff R,Hoff PM,Tabacof J,Katz A,Simon SD,Gansl RC.Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.Int J Gastrointest Cancer 2002; 32:35-41
  • 6[6]Maisey NR,Norman AR,Hill A,Massey A,Oates J,Cunningham D.CA19-9 as a prognostic factor in inoperable pancreatic cancer:the implication for clinical trials.Br J Cancer 2005; 93:740-743
  • 7[7]Sawaki A,Kanemitsu Y,Mizuno N,Takahashi K,Nakamura T,Ioka T,Tanaka S,Nakaizumi A,Salem AA,Ueda R,Yamao K.Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine.J Gastroenterol Hepatol 2006; Epub ahead of print,DOI:10.1111/j.1440-1746.2006.04734.x
  • 8[8]Ebrahimi B,Tucker SL,Li D,Abbruzzese JL,Kurzrock R.Cytokines in pancreatic carcinoma:correlation with phenotypic characteristics and prognosis.Cancer 2004; 101:2727-2736
  • 9[9]Van Cutsem E,van de Velde H,Karasek P,Oettle H,Vervenne WL,Szawlowski A,Schoffski P,Post S,Verslype C,Neumann H,Safran H,Humblet Y,Perez Ruixo J,Ma Y,Von Hoff D.Phase Ⅲ trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.J Clin Oncol 2004; 22:1430-1438
  • 10[10]Ishii H,Okada S,Nose H,Yoshimori M,Aoki K,Okusaka T.Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy.Pancreas 1996; 12:267-271

共引文献13

同被引文献27

引证文献13

二级引证文献84

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部